Functionally, c-Myc acts primarily as a transcriptional regulator and has been described as a “master gene regulator,” exhibiting aberrant activation in a wide range of malignancies, including hematological cancers [62] as well as solid tumors such as breast [63], pancreatic [64], colorectal [65], and prostate cancers [66]. This evidence concerns the gene MYC and Familial prostate cancer.